Investigation and current representation of numerous patients in cases filed in New Jersey against Hoffman-LaRoche for injuries caused by Accutane (also known as roaccutane).
Accutane is a prescription drug used to treat serious acne. The side effects of Accutane, however, include the following severe and life threatening complications: catastrophic birth defects in developing fetuses; significantly decreased cognitive abilities; premature births and stillbirths; psychiatric disturbances, including depression, psychosis, emotional instability, suicidal ideations, and suicide; inflammatory bowel disease; vascular problems; liver toxicity, kidney damage, pancreatitis, ulcerative colitis; musculoskeletal problems, central nervous system and cardiovascular injuries; and auto-immune disease.
Juries across the country have found against Hoffman-LaRouche. In another major courtroom verdict linking powerful acne medication Accutane with long-term inflammatory bowel disease (IBD), an eight-person jury in Atlantic City has found that pharmaceutical maker Hoffman-La Roche failed to provide adequate warning of the possible condition to three patients who began taking the drug as teenagers and shortly thereafter developed severe forms of IBD. The jury awarded compensatory damages of $12.89 million to be apportioned among the three individuals, now aged in their mid-to-late 20s. The three plaintiffs were first prescribed Accutane nearly a decade ago while still in their teens to relieve adolescent acne. All three succumbed to various forms of IBD, including ulcerative colitis and Crohn's disease, while taking Accutane or shortly thereafter. As a result of their disease, all suffer from a dramatically increased risk of colon cancer. In reaching their verdict, jurors determined that Roche failed to adequately warn plaintiffs' prescribing physician about the risk of IBD from Accutane, and that Accutane was a substantial factor in causing the Plaintiffs' to develop IBD.
This is an important outcome and consistent with the recognition by the medical community that Accutane is a trigger for IBD.
Hoffman Roche faces as many as 600 Accutane cases around the country.
Do not change medications without first consulting your doctor.
Name (Stock Symbol)
Hoffman-LaRouche Ltd. is a pharmaceutical company.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.